| JPM |
Report |
EPS (Q2'26) |
BEAT |
pred ~$5.78 vs. cons $5.61 |
MEDIUM |
| JPM |
Report |
Markets/Trading revenue (Q2'26) |
BEAT |
pred ~$10.7B vs. cons ~$10.0B |
MEDIUM |
| JPM |
Report |
Net interest income (Q2'26) |
IN-LINE |
pred ~$25.8B vs. cons ~$25.6B |
MEDIUM |
| JPM |
Guide |
FY26 total NII guide |
BETTER |
guide ~$104B vs. cons ~$103B (FY2026) |
MEDIUM |
| JPM |
Guide |
FY26 adjusted expense guide |
LOWER |
guide ~$106B vs. cons ~$105B (FY2026) |
MEDIUM |
| JPM |
Guide |
FY26 card net charge-off rate guide |
UNCHANGED |
guide ~3.4% vs. cons ~3.4% (FY2026) |
MEDIUM |
| JPM |
Guide |
Reserve build / credit tone (Q2'26) |
UNKNOWN |
pred build ~$0.5B vs. cons ~$0.4B (Q2'26) |
LOW |
| JPM |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.5% |
— |
LOW |
| JPM |
Return |
5-day cumulative residual |
-0.8% (FADE) |
EPS/markets beat is largely priced in — stock sits ~1.4% below its early-July high, buy-side whispers already run above the Street, and UBS flags a 'messy' mega-bank day with high bars. A modest NII guide-raise is offset by higher expense guidance (good-problem spend that reads negatively) and no big rate-driven NII inflection (~20bps). Out-period math is roughly neutral-to-slightly-down: elevated Q1/Q2 markets run-rate is hard to extrapolate (pull-forward risk), so back-half revisions don't ratchet up enough to sustain a pop. Add succession/Epstein-letter Q&A overhang plus same-week CPI/PPI/Warsh rate cross-currents, and an initial relief bid tends to give back over the week. |
LOW |